

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7379560

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
RICHARD COPP	12/01/2020
CHRISTOPHER M. CIMARUSTI	11/27/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ESPERION THERAPEUTICS, INC.
<b>Street Address:</b>	3891 RANCHERO DRIVE
<b>Internal Address:</b>	SUITE 150
<b>City:</b>	ANN ARBOR
<b>State/Country:</b>	MICHIGAN
<b>Postal Code:</b>	48108
<b>PROPERTY NUMBERS Total: 5</b>	
<b>Property Type</b>	<b>Number</b>
<b>PCT Number:</b>	US2020038622
<b>Application Number:</b>	17150321
<b>Application Number:</b>	17150325
<b>Application Number:</b>	17577829
<b>Application Number:</b>	17742728
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)523-1231
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	617-570-1000
<b>Email:</b>	mbrodowski@goodwinlaw.com, lsolis@goodwinlaw.com, us-patentbos@goodwinlaw.com
<b>Correspondent Name:</b>	GOODWIN PROCTER LLP - PATENT ADMINISTRATOR
<b>Address Line 1:</b>	100 NORTHERN AVENUE
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02210
<b>ATTORNEY DOCKET NUMBER:</b>	ESP-006WO/C1/C2/C3/C4
<b>NAME OF SUBMITTER:</b>	MICHAEL H. BRODOWSKI
<b>SIGNATURE:</b>	/Michael H. Brodowski/
<b>DATE SIGNED:</b>	06/13/2022

PATENT

**Total Attachments: 5**

source=ESP-006WO Inventors to Esperion Assignment#page1.tif

source=ESP-006WO Inventors to Esperion Assignment#page2.tif

source=ESP-006WO Inventors to Esperion Assignment#page3.tif

source=ESP-006WO Inventors to Esperion Assignment#page4.tif

source=ESP-006WO Inventors to Esperion Assignment#page5.tif

## ASSIGNMENT

WHEREAS, we, Richard Copp, Mohamed Abdelnasser, and Christopher M. Cimarusti (“ASSIGNORS”), along with others, have invented one or more inventions described in an application (or provisional application) for Letters Patent of the United States entitled:

### **METHODS OF MAKING BEMPEDOIC ACID AND COMPOSITIONS OF THE SAME**

and identified by Attorney Docket No. ESP-006WO, which was filed in the U.S. Patent and Trademark Office as Receiving Office on June 19, 2020, and assigned International Application No. PCT/US2020/038622, which application claims priority to and the benefit of U.S. Patent Application No. 62/864,873, filed on June 21, 2019; and

WHEREAS, Esperion Therapeutics, Inc. (hereinafter “ASSIGNEE”), a company organized and existing under the laws of the State of Delaware and having a business address at 3891 Ranchero Drive, Suite 150, Ann Arbor, Michigan 48108, desires to acquire an interest therein, in accordance with agreements duly entered into with us;

NOW, THEREFORE, to all whom it may concern, be it known that for and in consideration of said agreements and of other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, we have sold, assigned and transferred and do hereby sell, assign and transfer unto said ASSIGNEE, its successors, assigns and legal representatives, at least as early as the filing date of said application, our entire right, title and interest, which ASSIGNEE accepts, in and throughout the United States of America, its territories and all foreign countries, in and to the invention(s) described in said application, together with our entire right, title and interest, which ASSIGNEE accepts, in and to said application and such Letters Patent as may issue thereon, and applications that claim priority thereto under United States law or international or foreign convention and such Letters Patent (including equivalent granting documents) that may issue thereon, including but not limited to non-U.S., international, non-provisional, continuation, divisional, continuation-in-part, reissue, reexamination, extension, and substitution applications of said application and such Letters Patent, and the right to claim priority to said application for any such applications and Letters Patent, and any right, title and interest we may have in invention(s) and applications to which said application claims priority including U.S. provisional and non-U.S. applications; said invention(s), applications and Letters Patent to be held and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held by us had this assignment and sale not been made; we hereby convey all of our rights arising under or pursuant to any and all United States laws and foreign and international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for Letters Patent, including but not limited to any cause(s) of action and damages accruing prior to this assignment, including all rights to exclude others from practicing the claimed invention(s) and all rights to seek any and all remedies in law or equity, including damages and injunctive relief, for past, present, and future infringement. We hereby acknowledge that this assignment, being of our entire right, title and interest in and to said invention(s) and applications, carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and

agents of ASSIGNEE's selection and the right to procure the grant of all Letters Patent to ASSIGNEE in its own name as assignee of our entire right, title and interest therein;

AND, we hereby further agree for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid invention(s) and applications to said ASSIGNEE, its successors, assigns, and legal representatives, but at its or their expense and charges, including the execution of papers for filing and prosecution of non-provisional, substitution, continuation, divisional, continuation-in-part, reissue, reexamination, and corresponding foreign and international patent applications;

AND, we hereby further agree to provide statements or testimony in any interference, derivation or post-grant proceeding, or other proceeding in which said invention(s) or any application or patent directed thereto may be involved;

AND, we hereby authorize ASSIGNEE or its attorneys or agents to insert the correct patent application number and filing date into this assignment, if none is indicated on the date of our execution of this assignment;

AND, we hereby authorize and request the Director of the United States Patent and Trademark Office and the empowered officials of all other governments to issue such Letters Patent as shall be granted upon said application, or applications based thereon, to said ASSIGNEE, its successors, assigns, or legal representatives.

IN TESTIMONY WHEREOF, we have duly executed on the date(s) set forth below this assignment, along with ASSIGNEE's authorized representative, where ASSIGNORS and ASSIGNEE may execute this Assignment in counterparts, in which case each executed counterpart will be considered to be an original.

*[Remainder of page intentionally left blank]*

**ASSIGNOR**

12-01-2020  
Date

Richard Copp  
Richard Copp

**Witness:**

12-01-2020  
Date

Della Copp  
Signature  
Name of Witness: Della Copp

**ASSIGNOR**

\_\_\_\_\_  
Date

\_\_\_\_\_  
Mohamed Abdelnasser

**Witness:**

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature  
Name of Witness: \_\_\_\_\_

**ASSIGNOR**

\_\_\_\_\_  
Date

\_\_\_\_\_  
Christopher M. Cimarusti

**Witness:**

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature  
Name of Witness: \_\_\_\_\_

*[Remainder of page intentionally left blank]*

**ASSIGNOR**

\_\_\_\_\_  
Date

\_\_\_\_\_  
Richard Copp

Witness:

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature  
Name of Witness: \_\_\_\_\_

**ASSIGNOR**

\_\_\_\_\_  
Date

\_\_\_\_\_  
Mohamed Abdelnasser

Witness:

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature  
Name of Witness: \_\_\_\_\_

**ASSIGNOR**

11/27/2020  
Date

Christopher M. Cimarusti  
Signature  
Christopher M. Cimarusti

Witness:

11/27/2020  
Date


Yvette Cimarusti  
Signature  
Name of Witness: YVETTE CIMARUSTI

*[Remainder of page intentionally left blank]*

Accepted by:

ASSIGNEE'S AUTHORIZED REPRESENTATIVE

Signature:



Representative's Name: Richard Bartram

Representative's Title: Chief Financial Officer

*[Remainder of page intentionally left blank]*